NovoCure Raises FY2026 Sales Guidance from $675.000M-$705.000M to $690.000M-$710.000M vs $692.115M Est

Benzinga Newsdesk www.benzinga.com Positive 94.1%

Neg 0% Neu 0% Pos 94.1%

NovoCure (NASDAQ:NVCR) raises FY2026 sales outlook from $675.000 million-$705.000 million to $690.000 million-$710.000 million vs $692.115 million estimate.